U.S. health officials warned Thursday about the risk of pneumonia with Cubist Pharmaceuticals Inc’s (CBST.O) flagship antibiotic. The Food and Drug Administration said patients treated with the intravenous antibiotic Cubicin may develop eosinophilic pneumonia, which causes a potentially fatal accumulation of white blood cells in the lungs.
